Results 111 to 120 of about 403,562 (281)

An ocean-sea ice model study of the unprecedented Antarctic sea ice minimum in 2016

open access: yesEnvironmental Research Letters, 2018
Overall Antarctic sea ice extent in the 2016 spring attained a record minimum for the satellite period (1979–2016), presenting an abrupt departure from the record maxima in previous years and the slight upward trend since 1979.
Kazuya Kusahara   +4 more
doaj   +1 more source

The sea ice model component of HadGEM3-GC3.1 [PDF]

open access: yes, 2017
A new sea ice configuration, GSI8.1, is implemented in the Met Office global coupled configuration HadGEM3-GC3.1 which will be used for all CMIP6 (Coupled Model Intercomparison Project Phase 6) simulations. The inclusion of multi-layer thermodynamics has
Blockley, Edward W.   +5 more
core   +2 more sources

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

open access: yesMolecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung   +17 more
wiley   +1 more source

Polar sea ice observations by means of microwave radiometry [PDF]

open access: yes
Principles pertinent to the utilization of 1.55 cm wavelength radiation emanating from the surface of the earth for studying the changing characteristics of polar sea ice are briefly reviewed.
Campbell, W. J.   +3 more
core   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

open access: yesMolecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang   +3 more
wiley   +1 more source

Large-scale drivers of the exceptionally low winter Antarctic sea ice extent in 2023

open access: yesFrontiers in Earth Science
The year 2023 marked a turning point for the Antarctic region as the Southern Hemisphere experienced a significant reduction in its sea ice extent, with a record-breaking sea ice minimum in July 2023 of approximately 2.4 million square kilometers below ...
Monica Ionita, Monica Ionita
doaj   +1 more source

The Arctic-Subarctic sea ice system is entering a seasonal regime: Implications for future Arctic amplification [PDF]

open access: yes, 2017
The loss of Arctic sea ice is a conspicuous example of climate change. Climate models project ice-free conditions during summer this century under realistic emission scenarios, reflecting the increase in seasonality in ice cover.
Haine, Thomas W. N., Martin, Torge
core   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

open access: yesMolecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee   +8 more
wiley   +1 more source

Sedimentation processes on the Antarctic continental margin at Kapp Norvegia during the Late Pleistocene [PDF]

open access: yes, 1986
Sedimentological analyses concerning ice rafted debris, grain size distribution, biogeneous components, and clay mineral composition of four sediment cores from the Antarctic continental margin off Kapp Norvegia reveal a cyclical pattern of three ...
Grobe, Hannes
core   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

open access: yesMolecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy